-
Innovation Ranking
NewInnovation Ranking – Diffusion Pharmaceuticals Inc
Diffusion Pharmaceuticals Inc (Diffusion), formerly Diffusion Pharmaceuticals LLC is a clinical stage biotechnology company. It develops standard of care therapies. The company improves cancer treatments such as radiation therapy and chemotherapy in treatment-resistant solid tumors, including multiple FDA orphan-designated indications. It offers new and small-molecule drugs for regulating the movement of oxygen into tissue and treatment for stroke, treatment- resistant cancerous tumors, glioblastoma multiforme,pancreatic cancer, brain metastases. Diffusion develops trans sodium crocetinate, a synthetic small molecule that improves the diffusion...
-
Product Insights
Cardiac Markers Rapid Tests and POC Pipeline by Development Stages, Segments, Region and Countries, Regulatory Path and Key Companies
Cardiac Markers Rapid Tests and POC Pipeline Market Report Overview Cardiac markers rapid tests & point of care (POC) are simple to perform rapid diagnostic tests that are ready to use, accurate, economical, and for infield use. These tests are suggested for individuals suspected of any indication. The Cardiac Markers Rapid Tests and POC pipeline market research report provides a comprehensive understanding of the pipeline products along with their comparative analysis at various stages of development. The report also includes...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – NX-5948 in Relapsed Chronic Lymphocytic Leukemia (CLL)
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - NX-5948 in Relapsed Chronic Lymphocytic Leukemia (CLL) report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. NX-5948 in Relapsed Chronic Lymphocytic Leukemia (CLL) Drug Details:...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – NX-5948 in Refractory Chronic Lymphocytic Leukemia (CLL)
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - NX-5948 in Refractory Chronic Lymphocytic Leukemia (CLL) report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. NX-5948 in Refractory Chronic Lymphocytic Leukemia (CLL) Drug Details:...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Varlilumab in Mantle Cell Lymphoma
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Varlilumab in Mantle Cell Lymphoma report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Varlilumab in Mantle Cell Lymphoma Drug Details: Varlilumab (CDX-1127) is...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Varlilumab in Marginal Zone B-cell Lymphoma
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Varlilumab in Marginal Zone B-cell Lymphoma report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Varlilumab in Marginal Zone B-cell Lymphoma Drug Details: Varlilumab...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Rituximab in Hairy Cell Leukemia
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Rituximab in Hairy Cell Leukemia report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Rituximab in Hairy Cell Leukemia Drug Details: Rituximab (MabThera, Rituxan,...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – PCLX-001 in Pancreatic Cancer
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - PCLX-001 in Pancreatic Cancer report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. PCLX-001 in Pancreatic Cancer Drug Details: PCLX-001 (DDD86481) is under development for...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Odronextamab in Primary Mediastinal B-Cell Lymphoma
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Odronextamab in Primary Mediastinal B-Cell Lymphoma report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Odronextamab in Primary Mediastinal B-Cell Lymphoma Drug Details: Odronextamab is...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – CX-2029 in Ovarian Cancer
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - CX-2029 in Ovarian Cancer report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. CX-2029 in Ovarian Cancer Drug Details: CX-2029 is under development for...